Suppliers and packagers for NAMENDA

NAMENDA

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Abbvie	NAMENDA	memantine hydrochloride	TABLET;ORAL	021487	NDA AUTHORIZED GENERIC	Actavis Pharma, Inc.	0591-3870-44	10 BLISTER PACK in 1 BOX, UNIT-DOSE (0591-3870-44) / 10 TABLET in 1 BLISTER PACK (0591-3870-45)	2015-04-01
Abbvie	NAMENDA	memantine hydrochloride	TABLET;ORAL	021487	NDA AUTHORIZED GENERIC	Actavis Pharma, Inc.	0591-3870-60	60 TABLET in 1 BOTTLE (0591-3870-60)	2015-04-01
Abbvie	NAMENDA	memantine hydrochloride	TABLET;ORAL	021487	NDA AUTHORIZED GENERIC	Actavis Pharma, Inc.	0591-3875-44	10 BLISTER PACK in 1 BOX, UNIT-DOSE (0591-3875-44) / 10 TABLET in 1 BLISTER PACK (0591-3875-45)	2015-04-01
Abbvie	NAMENDA	memantine hydrochloride	TABLET;ORAL	021487	NDA AUTHORIZED GENERIC	Actavis Pharma, Inc.	0591-3875-60	60 TABLET in 1 BOTTLE (0591-3875-60)	2015-04-01
Abbvie	NAMENDA	memantine hydrochloride	TABLET;ORAL	021487	NDA AUTHORIZED GENERIC	Actavis Pharma, Inc.	0591-3900-87	1 BLISTER PACK in 1 CARTON (0591-3900-87) / 1 KIT in 1 BLISTER PACK	2015-04-01
Abbvie	NAMENDA	memantine hydrochloride	TABLET;ORAL	021487	NDA AUTHORIZED GENERIC	Cardinal Health 107, LLC	55154-2666-0	10 BLISTER PACK in 1 BAG (55154-2666-0) / 1 TABLET in 1 BLISTER PACK	2015-04-01
Abbvie	NAMENDA	memantine hydrochloride	TABLET;ORAL	021487	NDA AUTHORIZED GENERIC	Cardinal Health 107, LLC	55154-2667-0	10 BLISTER PACK in 1 BAG (55154-2667-0) / 1 TABLET in 1 BLISTER PACK	2015-04-01

Namenda (Memantine HCl) Key Suppliers and Patent Landscape

Last updated: February 19, 2026

Namenda (memantine hydrochloride), an NMDA receptor antagonist, is a pharmaceutical product used to treat moderate to severe dementia of the Alzheimer's type. Its supply chain and patent status are critical for market access and competitive positioning. This analysis details key suppliers of memantine hydrochloride API and outlines the patent landscape impacting its commercialization.

What are the Key Suppliers of Memantine Hydrochloride API?

The production of memantine hydrochloride active pharmaceutical ingredient (API) involves specialized chemical synthesis. Several global manufacturers are recognized for their capability to produce this complex molecule at commercial scale and meet stringent pharmaceutical quality standards. Key suppliers include:

• Albany Molecular Research Inc. (AMRI), now Curia: AMRI has historically been a significant API supplier, offering custom synthesis and manufacturing services. They operate multiple facilities with cGMP (current Good Manufacturing Practice) compliance. Their involvement in memantine API production has been documented through supply agreements and industry reports. Curia, post-acquisition of AMRI, continues to offer broad API development and manufacturing services.

• Jubilant Biosys (part of Jubilant Life Sciences): Jubilant is a global integrated pharmaceutical company with a strong API manufacturing arm. They possess expertise in complex multi-step synthesis and have the capacity to produce a range of pharmaceutical ingredients. Jubilant Life Sciences has been identified as a manufacturer of memantine API.

• Dishman Carbogen Amcis Ltd.: This company is a global contract research and manufacturing organization (CRMO) with a strong focus on API development and commercialization. They offer services from early-stage development to commercial-scale manufacturing, adhering to global regulatory standards. Dishman Carbogen Amcis has been noted for its API production capabilities, including for neurological drugs.

• Divi's Laboratories: An Indian pharmaceutical company, Divi's Laboratories is a major manufacturer of generic APIs. They are known for their large-scale production facilities and efficient synthesis processes. Divi's has a broad portfolio of APIs, and memantine hydrochloride is among their offerings.

• Granules India Ltd.: Granules India is another prominent Indian API manufacturer with a global footprint. They specialize in the production of finished dosage forms and active pharmaceutical ingredients. Their manufacturing sites are FDA-approved and cGMP compliant. Granules India is recognized as a supplier of memantine HCl API.

These suppliers are crucial for both branded and generic manufacturers of memantine hydrochloride products. Their ability to consistently deliver high-quality API in sufficient quantities is a prerequisite for maintaining market supply. The selection of an API supplier typically involves rigorous qualification processes, including site audits, quality agreements, and long-term supply contracts, ensuring compliance with regulatory requirements and product specifications.

What is the Patent Status of Memantine Hydrochloride?

The patent landscape for memantine hydrochloride has evolved significantly since its initial development, transitioning from pioneer patents protecting the compound itself to formulation and method of use patents, and now largely dominated by generic market entries following patent expiries.

Original Compound Patents

The foundational patents for memantine hydrochloride covered the compound's chemical structure and its use. The primary patent holder was Merz Pharma GmbH & Co. KGaA, which developed and marketed the branded product Namenda.

• Composition of Matter Patents: These patents, which claim the molecule itself, are typically the strongest and longest-lasting. For memantine, these core patents have long since expired, paving the way for generic competition. The original U.S. patent for memantine was granted in the 1980s.

Formulation and Method of Use Patents

Following the initial composition of matter patents, innovator companies often seek patent protection for specific pharmaceutical formulations, delivery systems, and methods of using the drug for particular indications or patient populations.

• Extended-Release Formulations: To improve patient compliance and therapeutic profiles, extended-release (ER) formulations of memantine were developed. Patents protecting these specific ER formulations, such as the once-daily Namenda XR, provided a period of market exclusivity beyond the expiry of the basic compound patent. For instance, patents related to the extended-release dosage form of memantine hydrochloride have been a key focus in the post-composition patent era. These patents typically describe specific release mechanisms, excipients, or manufacturing processes that achieve the desired extended release profile.

  • Example: U.S. Patent No. 7,404,969, titled "Memantine extended release pharmaceutical composition," was a significant patent for the extended-release formulation. It was filed in 2003 and granted in 2008. While the patent itself has expired, its lifespan contributed to market exclusivity for certain ER products. The expiration of such key formulation patents directly impacts the market entry timeline for generic ER versions.

• Method of Use Patents: Patents can also be granted for specific methods of treating diseases with memantine. This could involve claims for using memantine to treat specific stages of Alzheimer's disease, or in combination with other therapies. However, these patents are generally weaker and more susceptible to challenges, especially once generic versions of the drug are available.

Generic Competition and Patent Litigation

The expiry of primary composition of matter patents and key formulation patents has led to significant generic competition for memantine hydrochloride. This often involves patent litigation as generic manufacturers seek to launch their products and innovator companies defend their remaining patent protections.

• Hatch-Waxman Act Provisions: In the United States, the Hatch-Waxman Act (Drug Price Competition and Patent Term Restoration Act of 1984) governs the process for generic drug approval and patent challenges. Generic companies file Abbreviated New Drug Applications (ANDAs) and may challenge existing patents.

• Key Litigation Trends: Litigation surrounding memantine patents has focused on the validity and infringement of formulation patents. Generic companies often argue that their formulations do not infringe existing patents or that the patents are invalid. These legal battles determine when generic versions can enter the market and at what price. The U.S. Food and Drug Administration (FDA) maintains the "Orange Book," which lists patents and exclusivity periods for approved drugs. This book is a critical resource for understanding the patent status and potential generic entry dates.

Current Market Status

As of late 2023 and into 2024, the market for memantine hydrochloride is largely characterized by generic competition. The once-daily extended-release formulations, which held a degree of patent protection, have also seen generic entrants following the expiration of their associated patents. This has resulted in significant price erosion for memantine products.

The patent landscape for memantine hydrochloride, while once a strong barrier to entry, has largely matured. Companies involved in the memantine market, whether for branded or generic products, must monitor the remaining formulation patents, potential new patent filings for novel delivery systems or combinations, and the ongoing legal challenges that shape market access and profitability.

What are the Regulatory Considerations for Namenda API?

The production and supply of memantine hydrochloride API are subject to stringent regulatory oversight by health authorities worldwide to ensure patient safety and product efficacy. Key regulatory considerations include:

• Good Manufacturing Practices (GMP): Manufacturers of memantine API must adhere to cGMP guidelines established by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Japan's Pharmaceuticals and Medical Devices Agency (PMDA). GMP compliance ensures that APIs are consistently produced and controlled according to quality standards appropriate for their intended use. This involves robust quality management systems, detailed documentation, validated processes, and trained personnel.

• Drug Master Files (DMFs): API manufacturers typically file Drug Master Files (DMFs) with regulatory agencies. A DMF is a submission to a regulatory agency that may be used to provide confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. For memantine HCl, a DMF allows regulatory agencies to review the API manufacturing details confidentially, while the drug product applicant (e.g., a generic drug company) can reference the DMF in their own regulatory submission (e.g., an ANDA).

• Impurity Profiling and Control: Regulatory agencies require thorough characterization of the API, including identification and quantification of impurities. This includes process-related impurities, degradation products, and residual solvents. Manufacturers must demonstrate that impurity levels are within acceptable limits, often defined by ICH (International Council for Harmonisation) guidelines. For memantine HCl, specific impurities related to its synthesis pathway must be carefully monitored and controlled.

• Stability Testing: Comprehensive stability studies are required to determine the shelf-life of the memantine hydrochloride API under various storage conditions. These studies assess how the API's quality attributes change over time, ensuring that it remains within its specifications throughout its designated shelf life.

• Audits and Inspections: API manufacturing sites are subject to regular inspections by regulatory authorities and audits by their pharmaceutical clients. These inspections verify ongoing compliance with GMP and other relevant regulations. Successful inspections are critical for maintaining regulatory approval and supply chain continuity.

• Supply Chain Security and Traceability: Regulatory bodies are increasingly focused on supply chain integrity. Manufacturers and their clients must ensure that the memantine API is sourced from approved, qualified suppliers and that the supply chain is secure and traceable to prevent counterfeiting and diversion.

• Post-Approval Changes: Any changes to the manufacturing process, facilities, or specifications of memantine HCl API must be carefully evaluated and, if necessary, reported to or approved by regulatory agencies. This ensures that changes do not adversely affect the quality, safety, or efficacy of the final drug product.

Adherence to these regulatory requirements is non-negotiable for API suppliers. Failure to comply can lead to regulatory actions, including warning letters, import alerts, and ultimately, the inability to supply the API for use in approved pharmaceutical products, significantly impacting the availability of Namenda and its generic equivalents.

What is the Market Size and Competition for Memantine Hydrochloride?

The market for memantine hydrochloride has experienced shifts due to patent expirations and the subsequent influx of generic competition. Understanding its market size and competitive dynamics is essential for strategic planning.

Market Size and Growth

The global market for memantine hydrochloride has historically been substantial, driven by the prevalence of Alzheimer's disease and the drug's efficacy in managing symptoms of moderate to severe dementia.

• Pre-Generic Market: Before widespread generic availability, the branded Namenda (and its extended-release versions) generated significant revenue for its developer. Market size figures from the peak of branded exclusivity were in the hundreds of millions of U.S. dollars annually.

• Post-Generic Market: With the advent of generic memantine hydrochloride, the market dynamics have transformed. The overall market value has decreased due to significant price reductions driven by competition. However, the volume of memantine prescribed and dispensed has likely increased due to its affordability. Estimating the precise current market size is challenging as it is fragmented among numerous generic manufacturers. However, global sales are still in the hundreds of millions of dollars, with significant portions originating from the U.S. and European markets. The market is projected to grow at a moderate pace, influenced by an aging global population and continued demand for Alzheimer's treatments.

Competitive Landscape

The competitive landscape for memantine hydrochloride is now dominated by generic pharmaceutical manufacturers.

• Key Generic Players: Numerous companies globally manufacture and market generic memantine hydrochloride tablets and oral solutions. These include:

  • Teva Pharmaceuticals
  • Sun Pharmaceutical Industries
  • Apotex Inc.
  • Mylan N.V. (now Viatris)
  • Dr. Reddy's Laboratories
  • Actavis (now part of Teva)
  • Endo International plc

• Branded vs. Generic Dynamics: The primary competition is between branded Namenda (and its XR formulations, where still under some exclusivity) and a multitude of generic alternatives. Generic manufacturers compete primarily on price, manufacturing efficiency, and market access through contracts with pharmacy benefit managers and healthcare systems.

• Product Formulations: Competition exists for both immediate-release and extended-release (XR) formulations. The XR versions, having had later patent protection, faced generic entry at a later stage, but are now also subject to intense generic competition.

• Geographic Variations: The intensity of competition and market share distribution can vary by region. Markets with established generic drug approval pathways and robust healthcare systems tend to have more aggressive generic competition.

• API Supplier Influence: The competitive positioning of generic drug manufacturers is also influenced by their relationships with reliable and cost-effective API suppliers. Securing a consistent supply of high-quality memantine HCl API is a critical factor in maintaining market share and profitability in this highly competitive generics market.

The current market for memantine hydrochloride is characterized by intense price competition and a large number of generic suppliers vying for market share. Success in this environment depends on efficient manufacturing, strong supply chain management, and effective market penetration strategies.

Key Takeaways

• Critical API Suppliers Identified: Curia (formerly AMRI), Jubilant Biosys, Dishman Carbogen Amcis, Divi's Laboratories, and Granules India are key global manufacturers of memantine hydrochloride API, vital for both branded and generic drug production.
• Evolved Patent Landscape: Original compound patents for memantine hydrochloride have expired, leading to generic market entry. Protection for extended-release formulations and specific methods of use has provided periods of exclusivity but is also now largely subject to generic challenges and expirations.
• Stringent Regulatory Requirements: API production must adhere to strict cGMP standards, with comprehensive DMF filings, impurity controls, stability testing, and regulatory inspections being mandatory for market access.
• Shift to Generic Dominance: The memantine hydrochloride market, once driven by branded Namenda, is now dominated by generic manufacturers. This has led to significant price erosion but also increased accessibility.
• Competitive Market Dynamics: The market is highly competitive, with numerous generic players vying for market share based on price, manufacturing efficiency, and supply chain reliability.

FAQs

1. Which companies are the primary holders of expired patents for memantine hydrochloride? Merz Pharma GmbH & Co. KGaA was the original developer and marketer of branded Namenda and held the initial key patents for memantine hydrochloride.

2. What is the primary indication for Namenda (memantine hydrochloride)? Namenda is primarily indicated for the treatment of moderate to severe dementia of the Alzheimer's type.

3. How do regulatory bodies ensure the quality of memantine hydrochloride API? Regulatory bodies like the FDA and EMA ensure API quality through cGMP compliance, review of Drug Master Files (DMFs), rigorous impurity profiling, stability testing, and site inspections.

4. What impact has patent expiration had on the price of memantine hydrochloride? Patent expiration has led to the entry of generic competitors, resulting in a significant decrease in the price of memantine hydrochloride products.

5. Are there ongoing patent disputes related to memantine hydrochloride formulations? While core patents have expired, litigation can still occur around specific formulation patents as generic companies seek to launch or challenge existing protections. Information on current disputes is best found through legal databases and pharmaceutical news services tracking patent litigation.

---

Citations

[1] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.fda.gov/drugs/therapeutic-equivalence-drug-list/orange-book-approved-drug-products-therapeutic-equivalence-evaluations (Note: This is a general reference to the Orange Book as a resource for patent and exclusivity information, specific entries would be product and patent number dependent).

[2] U.S. Patent No. 7,404,969. (2008). Memantine extended release pharmaceutical composition. Retrieved from USPTO Patent Full-Text and Image Database. (Note: Direct access to the patent document is required for full details).

[3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from https://www.ich.org/ (Note: General reference to ICH guidelines concerning impurities, stability, and quality).